GLP-1 patches for weight loss: what the science actually says

What did @hifortesa actually say?

Not much, honestly, and that's worth noting. The creator didn't make medical claims. They asked a crowd-sourcing question: have you tried "Azepic patches" and what happened? This is a journalism callout, not a health claim. Give them credit for being transparent about their intent.

The video is short, neutral in tone, and explicitly frames the topic as something being investigated rather than endorsed. The creator is looking for sources, not dispensing medical advice. That said, 23,500 people watched this, and many of them likely landed on it while actively looking for information about GLP-1 patches, which means the video exists inside a much messier ecosystem of misinformation, even if the video itself isn't the problem.

Does the science back GLP-1 patches up?

No. Not yet, and the gap between "not yet" and "never" matters here. Currently, there is no FDA-approved transdermal patch that delivers semaglutide, tirzepatide, liraglutide, or any other GLP-1 receptor agonist. The science has a real reason for that.

GLP-1 peptides are large molecules. Semaglutide, for example, has a molecular weight of roughly 4,114 daltons. Transdermal drug delivery generally works best with small, lipophilic molecules under 500 daltons, a principle sometimes called Lipinski's rule of five (Lipinski et al., 2001, Advanced Drug Delivery Reviews). Getting a molecule the size of semaglutide through intact skin in therapeutically relevant concentrations is, as of now, not demonstrated in peer-reviewed human trials. Some research groups are exploring microneedle arrays as a delivery mechanism for peptide drugs, and early animal data is interesting (Zhang et al., 2023, ACS Nano), but animal data is not human data, and interesting is not approved.

Anyone selling a patch claiming to deliver functional GLP-1 agonists is selling something that outpaces the current evidence base significantly.

What did they get wrong, or right?

The creator got the framing right: they called it a story they're investigating, not a product they're recommending. They also got the cultural observation right. GLP-1 patches are genuinely spreading across TikTok, and the phenomenon deserves journalistic scrutiny.

What they didn't do, which would have added value, is flag that these products are not FDA-approved and that the underlying pharmacology makes the efficacy claims implausible. A journalist asking "what's going on" without seeding the conversation with that basic context risks letting viewers assume the patches are a legitimate alternative to injectable GLP-1 medications.

The name "Azepic" is also worth flagging. It doesn't correspond to any known regulated pharmaceutical product. Products with invented brand names in this space are often compounded, unapproved, or outright counterfeit. Compounded drugs are not equivalent to FDA-approved brand-name medications, a distinction the FDA has specifically addressed in its guidance on compounded semaglutide (FDA, 2024).

What should you actually know?

If you're seeing GLP-1 patches marketed on TikTok or elsewhere, here is what the current evidence supports. No transdermal GLP-1 patch has cleared FDA approval. The molecular size of GLP-1 agonists makes skin delivery pharmacologically difficult with current technology. Products sold as patches containing semaglutide or similar peptides are either delivering negligible amounts of the active compound or are making claims that cannot be verified without peer-reviewed human pharmacokinetic data.

The approved delivery methods for GLP-1 receptor agonists are subcutaneous injection and, for oral semaglutide specifically, a tablet formulation (Rybelsus), which uses a novel absorption enhancer to bypass the gut barrier (Davies et al., 2019, JAMA). Even oral semaglutide required years of clinical development to demonstrate adequate bioavailability.

• No patch-based GLP-1 product is currently FDA-approved.
• Semaglutide is too large a molecule for standard transdermal delivery.
• Compounded semaglutide products are not the same as brand-name Ozempic or Wegovy.
• If a product doesn't have published human pharmacokinetic data, its efficacy claims are unsupported.